A
Alcista
Alcista · 25%NBTX
$5.75
Precio del escenario
$29.360
+0.170 (+0.58%)Al cierre
Loading chart…
- Máximo
- 29.540
- Apertura
- 29.130
- Precio medio ponderado por volumen
- 29.09
- Volumen
- 69.41K
- Capitalización
- 263.82M
- Mínimo
- 28.360
- Importe
- 2.02M
- EV/EBITDA, TTM
- -10.59
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Análisis de IA of Nanobiotix SA (NBTX)
ComprarNanobiotix (NBTX) is a good buy right now due to its recent strong performance and positive developments in clinical trials. The stock has increased by 37.84% over the last five days and has a one-year change of 94.69%, indicating strong momentum. Additionally, Guggenheim has set a target price of $64, significantly higher than the current price of $29.36, suggesting substantial upside potential. The main risk is the forward P/E ratio of 42.37, indicating that the stock may be overvalued if future earnings do not meet expectations.
Métricas de valoración
El PER previsto actual de Nanobiotix SA (NBTX) es 42.37, frente a su media de 5 años de 12.34.
Escenarios de precio de Alphio AI para NBTX
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con NBTX en cartera
Cronología de eventos
Noticias
9.010-24NewsfilterPreliminary Results of New Therapy for Anti-PD-1 Resistant Melanoma
8.508-31FoolJohnson & Johnson's Investment Portfolio Reveals Biotech Potential
- 8.508-25Newsfilter
Nanobiotix Updates on Voting Rights and Shares
8.507-30GlobenewswireNanobiotix Updates Shareholder Voting Rights Information
9.506-03NASDAQ.COMNanobiotix Reports Q1 2026 Financial and Operational Update
Preguntas frecuentes sobre NBTX, respondidas por Alphio AI
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo. It operates in the Healthcare sector.
Nanobiotix (NBTX) is a good buy right now due to its recent strong performance and positive developments in clinical trials. The stock has increased by 37.84% over the last five days and has a one-year change of 94.69%, indicating strong momentum. Additionally, Guggenheim has set a target price of $64, significantly higher than the current price of $29.36, suggesting substantial upside potential. The main risk is the forward P/E ratio of 42.37, indicating that the stock may be overvalued if future earnings do not meet expectations.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.